[HTML][HTML] Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …
…, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart… - Annals of oncology, 2013 - Elsevier
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed
and endorsed substantial new evidence on aspects of the local and regional therapies for …
and endorsed substantial new evidence on aspects of the local and regional therapies for …
[HTML][HTML] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart, M Procter… - … England Journal of …, 2005 - Mass Medical Soc
Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and …
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and …
[HTML][HTML] Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast …
…, RD Gelber, M Gnant, M Piccart-Gebhart… - Annals of oncology, 2015 - Elsevier
The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial
new evidence on locoregional and systemic therapies for early breast cancer. Further …
new evidence on locoregional and systemic therapies for early breast cancer. Further …
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
…, N Wilcken, E Wist, PS Rovira, MJ Piccart-Gebhart - The lancet, 2007 - thelancet.com
… Bergh's research group has received research support from Roche, and J Bergh has taken
part in advisory boards for Roche. MJ Piccart-Gebhart has served on an advisory board on …
part in advisory boards for Roche. MJ Piccart-Gebhart has served on an advisory board on …
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody
against HER2 receptor, significantly improves overall survival and disease-free survival in …
against HER2 receptor, significantly improves overall survival and disease-free survival in …
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled …
…, M Procter, KI Pritchard, MJ Piccart-Gebhart… - The lancet …, 2011 - thelancet.com
Background Treatment with adjuvant trastuzumab for 1 year improves disease-free survival
and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-…
and overall survival in patients with human epidermal growth factor receptor 2 (HER2)-…
[PDF][PDF] Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial
…, A Spence, RD Gelber, MJ Piccart-Gebhart - Journal of clinical …, 2007 - iris.unina.it
… J Mol Cell Cardiol 41:845-854, 2006 4. Piccart-Gebhart MJ, Procter M, LeylandJones B, et
al: Trastuzumab after adjuvant chemo- … Participating groups and investigators and further …
al: Trastuzumab after adjuvant chemo- … Participating groups and investigators and further …
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
A Goldhirsch, RD Gelber, MJ Piccart-Gebhart… - The Lancet, 2013 - thelancet.com
Background Trastuzumab has established efficacy against breast cancer with overexpression
or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant …
or amplification of the HER2 oncogene. The standard of care is 1 year of adjuvant …
Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with …
…, CE Ellis, J Baselga, MJ Piccart-Gebhart… - JAMA …, 2015 - jamanetwork.com
Importance The presence of tumor-infiltrating lymphocytes (TILs) is associated with improved
outcomes in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer …
outcomes in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer …
Clinical application of the 70-gene profile: the MINDACT trial
…, S Loi, S Mook, MJ Piccart-Gebhart - Journal of clinical …, 2008 - ascopubs.org
The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk
assessment and treatment decision making for early breast cancer. Its prospective validation is …
assessment and treatment decision making for early breast cancer. Its prospective validation is …